Neuphoria Therapeutics (NASDAQ:NEUP) Upgraded by Wall Street Zen to “Hold” Rating

Neuphoria Therapeutics (NASDAQ:NEUP) was upgraded by equities research analysts at Wall Street Zen to a “hold” rating in a report issued on Saturday.

NEUP has been the subject of several other research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Neuphoria Therapeutics in a research note on Monday, June 1st. HC Wainwright downgraded shares of Neuphoria Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, May 15th. One analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $21.00.

Neuphoria Therapeutics Stock Down 7.1%

Neuphoria Therapeutics stock opened at $3.64 on Friday. Neuphoria Therapeutics has a 12-month low of $3.19 and a 12-month high of $21.40. The business’s 50-day moving average price is $4.29 and its two-hundred day moving average price is $4.39. The stock has a market cap of $19.66 million, a PE ratio of -0.33 and a beta of 0.74.

Neuphoria Therapeutics (NASDAQ:NEUP) last posted its earnings results on Friday, May 15th. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.47. As a group, analysts expect that Neuphoria Therapeutics will post -4.07 earnings per share for the current year.

Institutional Investors Weigh In On Neuphoria Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Commonwealth Equity Services LLC bought a new stake in Neuphoria Therapeutics during the 4th quarter worth approximately $43,000. XTX Topco Ltd bought a new stake in shares of Neuphoria Therapeutics in the fourth quarter worth $47,000. Persistent Asset Partners Ltd increased its holdings in Neuphoria Therapeutics by 173.1% in the fourth quarter. Persistent Asset Partners Ltd now owns 13,403 shares of the company’s stock valued at $52,000 after purchasing an additional 8,495 shares during the period. Boothbay Fund Management LLC acquired a new position in Neuphoria Therapeutics during the 4th quarter worth about $54,000. Finally, Bridgeway Capital Management LLC bought a new stake in shares of Neuphoria Therapeutics in the 4th quarter valued at about $57,000. 15.90% of the stock is currently owned by institutional investors and hedge funds.

About Neuphoria Therapeutics

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.